CD105 inhibitor carotuximab. Forty percent of those patients experienced progression-free survival, based on radiographic imaging.

[Scout4answers]

From MaleCare newsletter

Looks very interesting...

sciencedaily.com/releases/2...

[cesanon]

What is a CD105 inhibitor and who would be most interested in it, and who would be least interested in it?

[Scout4answers in reply to cesanon]

New randomized studies will use certain biomarkers to try and answer this question.

mab class of drug sounds like maybe a immuneo type?

[Scout4answers in reply to cesanon]

From Wikipedia, the free encyclopedia

Carotuximab

Monoclonal antibody

Source Chimeric (mouse/human)

Target endoglin

Other names TRC-105

Carotuximab (INN[1]) (TRC-105) is a chimeric monoclonal antibody designed for the treatment of cancer.

This drug was developed by Tracon Pharmaceuticals Inc.[2]

It is at Phase III trials for angiosarcoma.

[Scout4answers in reply to cesanon]

PRESS RELEASE

<< Back

Printer Friendly

TRACON Pharmaceuticals Announces Termination Of Phase 3 TAPPAS Trial Based On The Recommendation Of The Independent Data Monitoring Committee

Company to Host Investor Conference Call Today at 8:30 a.m. EDT / 5:30 a.m. PDT

SAN DIEGO, April 12, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and, through our license to Santen Pharmaceutical Co. Ltd., wet age-related macular degeneration, today announced that its Phase 3 TAPPAS trial evaluating TRC105 in combination with Votrient (pazopanib) in patients with advanced or metastatic angiosarcoma was terminated for futility based on the recommendation of the Independent Data Monitoring Committee (IDMC) following its review of interim unblinded safety and efficacy data from more than 120 patients enrolled in the trial at the time of the analysis.

TRACON will work with investigators to appropriately conclude the study in a manner consistent with the best interests of each patient. Data from this study will be analyzed and submitted for presentation at an upcoming scientific congress.

“We are disappointed that TRC105 in combination with Votrient did not demonstrate clinically meaningful efficacy in patients with advanced or metastatic angiosarcoma,” said Charles Theuer, M.D. Ph.D., President and CEO of TRACON. “Given these data, we will terminate further enrollment in company sponsored trials of TRC105 in oncology. We will continue to support our partner, Santen, in their development of DE-122 in wet AMD, where the anti-angiogenic and anti-fibrotic properties of endoglin inhibition may be more relevant than in oncology. We will also continue to develop our other drug candidates, including TRC253 in partnership with Janssen and TJ004309 (also known as TJ-D5) in partnership with I-Mab, and, intend to advance candidates within I-Mab’s broad bispecific pipeline into the clinic in the US as early as the beginning of next year. We will also continue our business development efforts to source additional innovative products to fortify our pipeline through risk share and cost share arrangements. On a financial note, as a result of the expected savings to be generated from terminating TRACON sponsored trials of TRC105, we anticipate our current cash runway will now extend into the third quarter of 2020.”

[tango65]

Very interesting. If it works it is what everybody with CRPC needs.

[Benkaymel in reply to tango65]

Well, 40% of everybody with CRPC, but still gives another avenue of hope.

[tango65 in reply to Benkaymel]

Everybody will needed it, 40% will respond. For an advanced cancer therapy a 40% response it is not something to ignore.

[Scout4answers in reply to tango65]

We really don't know how selectively the drug was given in the small study

[Benkaymel in reply to tango65]

I agree and was trying to say the same thing. We don't know if we're in the 40% or not so have to take it and hope we are.

[Spyder54]

thanks Scout. Also Splice Variants blocked. Only 9 in study w 40% good response. Did the study say how long they avoided biochemical recurrence? Thanks, Mike